LexaGene Begins FDA EUA Study for Point-of-Care COVID-19 Testing
by Press Release from Outbreak News Today on (#5C82G)
Molecular diagnostics company, LexaGene, announce that it has started a series of studies required by the FDA for Emergency Use Authorization (EUA) testing for its COVID-19 assay in a point-of-care (POC) environment using its fully automated MiQLabTM system. Dr. Jack Regan, LexaGene's CEO and Founder states, I'm excited we have progressed to the point where we [...]
The post LexaGene Begins FDA EUA Study for Point-of-Care COVID-19 Testing appeared first on Outbreak News Today.